Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China

Xin Guana School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaView further author information

Hongchao Lia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaView further author information

Xiaomo Xionga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaView further author information

Cike Pengc Eli Lilly China Drug Development and Medical Affairs Center, Shanghai, ChinaView further author information

Ning Wangc Eli Lilly China Drug Development and Medical Affairs Center, Shanghai, ChinaView further author information

Xiao Mac Eli Lilly China Drug Development and Medical Affairs Center, Shanghai, ChinaView further author information

Aixia Maa School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaCorrespondence[email protected]
View further author information

show all

Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date